AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
Casting aside CRISPR scissors and making a point with base editorsDr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at Share XCasting aside CRISPR scissors and making a point with base editorshttps://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
Gilead needs deal-maker CEO after Milligan quitsGilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of Share XGilead needs deal-maker CEO after Milligan quitshttps://pharmaphorum.com/news/gilead-needs-deal-maker-ceo-after-milligan-quits-analyst/
Hep C woes to continue – but Gilead willing to acquire againGilead recorded a loss of $3.9 billion in Q4 because of a one-off charge linked to US tax Share XHep C woes to continue – but Gilead willing to acquire againhttps://pharmaphorum.com/news/hep-c-woes-continue-gilead-willing-acquire/
